과체중인 여성에서 체중 감소 보조제를 이용한 체중 및 내장지방의 감소 효과

The Effect of a Potential Antiobesity-Supplement on Weight Loss and Visceral Fat Accumulation in Overweight Women

  • 차보람 (연세대학교 식품영양학과, 의과대학 심장내과) ;
  • 채지숙 (연세대학교 식품영양학과, 의과대학 심장내과) ;
  • 이종호 (연세대학교 식품영양학과, 의과대학 심장내과) ;
  • 장양수 (연세대학교 식품영양학과, 의과대학 심장내과) ;
  • 이진희 (CJ(주) 식품연구소) ;
  • 손종욱 (CJ(주) 식품연구소)
  • 발행 : 2003.06.01

초록

Chitosan, hydroxycitrate and L-carnitine have been known to be antiobesity components. The purpose of this study was to evaluate the combined effects of chitosan, hydroxycitrate and L-carnitine mixture as a potential antiobesity supplement in overweight women. Pre-menopausal healthy females who were overweight (percent ideal body weight > 110) were included in this study. Forty-nine subjects randomly received a placebo (n = 25) or antiobesity-supplement (n = 24), which was a mixture of chitosan, hydroxycitrate, and L-carnitine. Before and after the eight-week experimental period, anthropometric parameters, blood components and computerized tomography were measured. At baseline, the two groups were well matched in terms of age, body mass index and lipid profile. After the eight weeks of potential antiobesity supplementation, the subjects' body fat percent had decreased significantly (p < 0.001) by 5.6% (39.1 $\pm$ 1 vs 36.9 $\pm$ 1%) while lean body mass increased (p < 0.01). Vsceral fat area at the L4 vertebra decreased significantly (p < 0.01) by 8.6% in the supplemented group and the total fat area at the L4 vertebra showed a tendency to decrease (p = 0.051) by 2.4%. Also, in the group given the antiobesity-supplement rather than the placebo, the fasting triglyceride level decreased significantly (p < 0.05) by 10.0%. In addition, serum total cholesterol levels in the antiobesity-supplement group showed a tendency to decrease (p=0.159) by 2.7% (194 $\pm$ 6 vs 189 $\pm$ 6 mg/dl). No side effects were found in either group during the intervention. In conclusion, the present study demonstrated that taking a mixture of chitosan, hydroxycitrate, and L-carnitine as a potential antiobesity supplement for eight weeks produced advantageous changes in the weight and visceral fat accumulation of overweight women without any side effects. (Korean J Nutrition 36(5): 483~490, 2003)

키워드

참고문헌

  1. Arch Intern Med v.161 no.13 Impact of overweight on the risk of developing common chronic diseases during a 10-year period Field,A.E.;Coakley,E.H.;Must,A.;Spadano,J.L.;Laird,N.;Dietz,W.H.;Rimm,E.;Colditz,G.A. https://doi.org/10.1001/archinte.161.13.1581
  2. BMJ v.325 no.7367 Management of overweight and obese adults Noel,P.H.;Pugh,J.A. https://doi.org/10.1136/bmj.325.7367.757
  3. Clin Obstet Gynecol v.45 no.4 Managing overweight and obesity in women Klauer,J.;Aronne,L.J. https://doi.org/10.1097/00003081-200212000-00016
  4. J Am Diet Assoc v.98 no.4 Persons successful at long-term weight loss and maintenance continue to consume a low-energy, low-fat diet Shick,S.M.;Wing,R.R.;Klem,M.L.;McGuire,M.T.;Hill,J.O.;Seagle,H. https://doi.org/10.1016/S0002-8223(98)00093-5
  5. Obes Res v.9 no.6 Comparative evaluation of fecal fat excretion induced by orlistat and chitosam Guerciolini,R.;Radu-Radulescu, L.;Boldrin,M.;Dallas,J.;Moore,R. https://doi.org/10.1038/oby.2001.47
  6. EXS v.87 Clinical and biochemical evaluation of chitosan for hypercholesterolemia and overweight control Muzzarelli,R.A.
  7. J Am Coll Nutr v.21 no.5 A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans Gallaher,D.D.;Gallaher,C.M.;Mahrt,G.J.;Carr,T.P.;Hollingashead,C.H.;Hesslink,R. Jr.;Wise,J. https://doi.org/10.1080/07315724.2002.10719246
  8. J Agric Food Chem v.50 no.1 Chemistry and biochemistry of (-) hydroxycitric acid from Garcinia Jena,B.S.;Jayaprakasha,G.K.;Singh,R.P.;Sakariah,K.K. https://doi.org/10.1021/jf010753k
  9. JAMA v.280 no.18 Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent:a randomized controlled trial Heymsfield,S.B.;Allison,D.B.;Vasselli,J.R.;pietrobelli,A.;Greenfield,D.;Nunez,C. https://doi.org/10.1001/jama.280.18.1596
  10. Int J Obes Relat Metab Disord v.26 no.6 The effect of (-) hydroxycitrate on energy intake and satiety in overweight humans Westerterp-Plantenga, M.S.;Kovacs,E.M. https://doi.org/10.1038/sj.ijo.0801979
  11. Physiol Rev v.63 no.4 Carnitine-metabolism and functions Bremer,J.
  12. Am J physiol v.238 no.5 Carnitine metabolism in normal-weight and obese human subjects during fasting Hoppel,C.L.;Genuth,S.M.
  13. Pro Soc Exp Biol Med v.141 no.1 Hypocholesterolemic effect of human growth hormone in coronary. Prone (type A) hypercholesterolemic subjects Friedman,M.;Byers,S.O.;Rosenman,R.H.;Li,C.H. https://doi.org/10.3181/00379727-141-36719
  14. The diet and health benefits of HCA(Hydroxycitric acid) Clouatre,D.;Rosenbaum,M.
  15. Am J Bariatr Med summer A non-prescription alternative on weight reduction therapy Conte,A.A.
  16. J Int Med Res v.28 no.5 A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin Thom,E. https://doi.org/10.1177/147323000002800505
  17. I. Lipogenesis.Lipids v.9 no.2 Effect of (-)hydroxycitrate upon the accumulation of lipid in the rat Sullivan,A.C.;Triscari,J.;Hamilton,J.G.;Miller,O.N.;Wheatley,V.R.
  18. Int J Sport Nutr Exerc Metab v.10 no.2 L-Carnitine supplementation combined with aerobic training does not promote weight loss in moderately obese women Villani,R.G.;Gannon,J.;Self,M.;Rich,P.A.
  19. Diabetes Res Clin Pract v.30 no.1 Changes in carnitine metabolism with ketone body production in obese glucose-intolerant patients Inokuchi,T.;Imamura,K.;Nomura,K.;Nomoto,K.;Isogai,S. https://doi.org/10.1016/0168-8227(95)01140-4
  20. Methods Find Exp Clin Pharmacol v.21 no.5 Decrease in serum LDL cholesterol with microcrystalline chitosan Wuolijoki,E.;Hirvela,T.;Ylitalo,P. https://doi.org/10.1358/mf.1999.21.5.793477
  21. Eur J Clin Nutr v.53 no.5 Randomized,double-blind trial of chitosan of chitosan for body weight reduction Pittler,M.H.;Abbot,N.C.;Harkness,E.F.;Ernst,E. https://doi.org/10.1038/sj.ejcn.1600733